MCID: HYP070
MIFTS: 38

Hyperpituitarism malady

Categories: Endocrine diseases

Aliases & Classifications for Hyperpituitarism

Aliases & Descriptions for Hyperpituitarism:

Name: Hyperpituitarism 12 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2444
MeSH 42 D006964
UMLS 69 C0020506

Summaries for Hyperpituitarism

MalaCards based summary : Hyperpituitarism is related to burning mouth syndrome type 3 and renal hypoplasia, bilateral. An important gene associated with Hyperpituitarism is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are TGF-Beta Pathway and Peptide ligand-binding receptors. The drugs Dopamine and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 71 Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones, it typically... more...

Related Diseases for Hyperpituitarism

Diseases related to Hyperpituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
id Related Disease Score Top Affiliating Genes
1 burning mouth syndrome type 3 10.3 POMC SST
2 renal hypoplasia, bilateral 10.3 POMC SST
3 water-clear cell adenoma 10.3 POMC SST
4 gershoni-baruch syndrome 10.2 PRL TRH
5 gmppa-cdg 10.2 GHRH SST
6 lung occult small cell carcinoma 10.2 PRL SST
7 grin2a-related speech disorders and epilepsy 10.2 GH1 PRL
8 critical congenital heart disease 10.2 GH1 IGF1
9 breast secretory carcinoma 10.2 POMC SST
10 wheat allergy 10.2 POMC PRL
11 endometrial mixed adenocarcinoma 10.2 POMC TRH
12 pancreatic colloid cystadenoma 10.2 POMC PRL
13 cardioauditory syndrome of sanchez cascos 10.2 GHRH IGF1 SST
14 paranasal sinus cancer, adult 10.2 INS SST
15 choline deficiency disease 10.2 INS SST
16 shaken baby syndrome 10.2 INS SST
17 macrocephaly, benign familial 10.2 GH1 POMC
18 deafness, autosomal dominant 25 10.2 GHR IGF1
19 brain ependymoma 10.2 INS SST
20 early-onset parkinson disease 10.2 POMC SST
21 vaginal adenoma 10.2 IGF1 POMC SST
22 hyperlipoproteinemia type iii 10.2 INS POMC
23 femur bifid with monodactylous ectrodactyly 10.1 IGF1 POMC
24 leukemia, acute promyelocytic, somatic 10.1 GHRH PRL SST
25 bone benign neoplasm 10.1 IGF1 POMC PRL
26 extragonadal nonseminomatous germ cell tumor 10.1 POMC PRL SST
27 nonparalytic poliomyelitis 10.1 POMC PRL SST
28 esophagus squamous cell papilloma 10.1 POMC PRL SST
29 bowen-conradi syndrome 10.1 AIP PRL
30 cerebral hemisphere lipoma 10.1 GH1 PRL SST
31 cockayne syndrome type i 10.1 INS PRL
32 osseous heteroplasia, progressive 10.1 GH1 IGF1 PRL
33 peripheral degeneration of cornea 10.1 INS SST
34 gemistocytic astrocytoma 10.1 GHRH SST
35 uterine ligament cancer 10.1 AIP IGF1 SST
36 hypogonadism cardiomyopathy 10.1 GH1 POMC
37 spinal stenosis 10.1 INS SST
38 sohval soffer syndrome 10.1 IGF1 IGFBP3
39 acute gonococcal salpingitis 10.1 POMC PRL TRH
40 tmem231-related joubert syndrome 10.1 IGF1 INS
41 epidural spinal canal meningioma 10.1 IGF1 INS PRL
42 mitochondrial complex ii deficiency 10.1 POMC SST
43 brain stem glioma 10.1 IGF1 INS SST
44 anisometropia 10.1 GH1 POMC SST
45 pinguecula 10.1 IGF1 INS PRL
46 photoparoxysmal response 3 10.1 INS SST
47 primary biliary cirrhosis 10.1 IGF1 INS PRL
48 capgras syndrome 10.1 IGF1 IGFBP3
49 adrenal adenoma 10.0 IGF1 INS POMC
50 sphingolipidosis 10.0 INS POMC PRL

Graphical network of the top 20 diseases related to Hyperpituitarism:



Diseases related to Hyperpituitarism

Symptoms & Phenotypes for Hyperpituitarism

MGI Mouse Phenotypes related to Hyperpituitarism:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 TRH AIP GHR GHRH IGF1 IGFBP3
2 growth/size/body region MP:0005378 9.97 IGFBP3 INS POMC SST TRH AIP
3 homeostasis/metabolism MP:0005376 9.96 AIP GHR GHRH IGF1 IGFBP3 INS
4 adipose tissue MP:0005375 9.8 GHR IGF1 IGFBP3 INS POMC
5 integument MP:0010771 9.7 AIP GHR IGF1 IGFBP3 INS POMC
6 liver/biliary system MP:0005370 9.5 AIP GHR GHRH IGFBP3 INS POMC
7 nervous system MP:0003631 9.23 GHR GHRH IGF1 INS POMC PRL

Drugs & Therapeutics for Hyperpituitarism

Drugs for Hyperpituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
2
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
5
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
6
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
7
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
8
Quinagolide Approved Phase 4 97805-50-0, 87056-78-8 105105
9
Zinc Approved Phase 4 7440-66-6 32051 23994
10
Metformin Approved Phase 4 657-24-9 14219 4091
11
Liraglutide Approved Phase 4 204656-20-2
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
13 insulin Phase 4,Phase 3,Phase 2
14 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2
15 Mitogens Phase 4,Phase 3,Phase 2
16
Serotonin Phase 4,Phase 3 50-67-9 5202
17 Serotonin 5-HT2 Receptor Antagonists Phase 4
18 Serotonin Agents Phase 4,Phase 3
19 Serotonin Antagonists Phase 4,Phase 3
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Complement Factor I Phase 4,Phase 3
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Tranquilizing Agents Phase 4,Phase 3,Phase 2
25 Paliperidone Palmitate Phase 4
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Dopamine Antagonists Phase 4,Phase 3
30 Dopamine D2 Receptor Antagonists Phase 4
31 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1
32 Hypoglycemic Agents Phase 4,Phase 2
33 Protective Agents Phase 4,Phase 1,Phase 2
34 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2
35 Psychotropic Drugs Phase 4,Phase 3,Phase 2
36 Antipsychotic Agents Phase 4,Phase 3,Phase 2
37 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
38 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
40
Lactitol Phase 4,Phase 3,Phase 1 585-86-4 3871
41 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Pharmaceutical Solutions Phase 4,Phase 2
43 Liver Extracts Phase 4
44 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
45
protease inhibitors Phase 4
46 Sitagliptin Phosphate Phase 4
47 HIV Protease Inhibitors Phase 4
48 Dipeptidyl-Peptidase IV Inhibitors Phase 4
49 Incretins Phase 4
50 Estradiol valerate Phase 4 979-32-8

Interventional clinical trials:

(show top 50) (show all 186)
id Name Status NCT ID Phase
1 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4
2 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4
3 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4
4 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
5 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4
6 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4
7 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4
8 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
9 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Completed NCT01861717 Phase 4
10 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4
11 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4
12 Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients Completed NCT01014793 Phase 4
13 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
14 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4
15 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4
16 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4
17 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4
18 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4
19 Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery Completed NCT00500227 Phase 4
20 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4
21 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4
22 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
23 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4
24 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4
25 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4
26 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4
27 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4
28 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4
29 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4
30 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4
31 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
32 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4
33 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
34 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4
35 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4
36 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4
37 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3
38 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3
39 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3
40 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3
41 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3
42 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3
43 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3
44 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3
45 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3
46 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3
47 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3
48 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3
49 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3
50 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3

Search NIH Clinical Center for Hyperpituitarism

Cochrane evidence based reviews: hyperpituitarism

Genetic Tests for Hyperpituitarism

Anatomical Context for Hyperpituitarism

MalaCards organs/tissues related to Hyperpituitarism:

39
Pituitary

Publications for Hyperpituitarism

Articles related to Hyperpituitarism:

id Title Authors Year
1
Congenital hyperpituitarism of hypothalamic origin: a new diencephalic syndrome with endocrine manifestations. ( 14444640 )
1959
2
Psychological findings in a case of von Recklinghausen's disease and hyperpituitarism. ( 13367234 )
1956
3
Further evidence that hyperthyroidism (Graves' disease) is not hyperpituitarism: effects of triiodothyronine and sodium iodide. ( 14367487 )
1955
4
Graves' disease: hyperthyroidism or hyperpituitarism. ( 13022743 )
1952
5
Creatine-creatinine metabolism in adult and juvenile hyperpituitarism. ( 18877070 )
1948
6
Hyperpituitarism and Hypopituitarism. ( 19312151 )
1940
7
Thyrotoxicosis with Unilateral Exophthalmos, Hyperpituitarism, and Infantile Hemiplegia. ( 19990197 )
1935
8
Case of Hyperpituitarism. ( 19984234 )
1925

Variations for Hyperpituitarism

Expression for Hyperpituitarism

Search GEO for disease gene expression data for Hyperpituitarism.

Pathways for Hyperpituitarism

Pathways related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 GH1 GHR GHRH IGF1 INS PRL
2
Show member pathways
13.18 GH1 GHR GHRH POMC PRL SST
3
Show member pathways
12.49 GH1 GHR IGF1 IGFBP3 INS
4
Show member pathways
11.91 GH1 GHR PRL
5 11.75 GH1 IGF1 INS
6
Show member pathways
11.72 GH1 IGF1 INS POMC
7 11.63 IGF1 IGFBP3 INS
8 11.56 IGF1 IGFBP3 INS
9 11.56 GH1 GHR IGF1 INS PRL
10 11.25 GH1 GHR IGF1
11 11.1 IGF1 INS
12
Show member pathways
11 POMC TRH
13 10.8 IGF1 IGFBP3
14
Show member pathways
10.74 GH1 GHR PRL

GO Terms for Hyperpituitarism

Cellular components related to Hyperpituitarism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 9.58 POMC PRL TRH
2 extracellular space GO:0005615 9.56 GH1 GHR GHRH IGF1 IGFBP3 INS
3 insulin-like growth factor ternary complex GO:0042567 9.37 IGF1 IGFBP3
4 endosome lumen GO:0031904 9.33 GH1 INS PRL
5 insulin-like growth factor binding protein complex GO:0016942 9.32 IGF1 IGFBP3
6 extracellular region GO:0005576 9.32 GH1 GHR GHRH IGF1 IGFBP3 INS
7 growth hormone receptor complex GO:0070195 9.26 GH1 GHR

Biological processes related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 GHRH IGF1 INS PRL
2 cellular protein metabolic process GO:0044267 9.78 IGF1 IGFBP3 INS PRL
3 cell-cell signaling GO:0007267 9.77 GHRH INS POMC SST TRH
4 positive regulation of MAPK cascade GO:0043410 9.71 IGF1 IGFBP3 INS
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 GH1 IGF1 INS
6 glucose transport GO:0015758 9.63 GH1 INS
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 GH1 GHR IGF1
8 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.62 GH1 GHR
9 JAK-STAT cascade GO:0007259 9.62 GH1 GHR
10 positive regulation of glucose import GO:0046326 9.61 IGF1 INS
11 hormone-mediated signaling pathway GO:0009755 9.61 GHR TRH
12 positive regulation of multicellular organism growth GO:0040018 9.61 GH1 GHR GHRH
13 activation of protein kinase B activity GO:0032148 9.6 IGF1 INS
14 positive regulation of mitotic nuclear division GO:0045840 9.59 IGF1 INS
15 response to food GO:0032094 9.58 GHR GHRH
16 regulation of multicellular organism growth GO:0040014 9.58 GHR IGF1 PRL
17 positive regulation of glycogen biosynthetic process GO:0045725 9.57 IGF1 INS
18 positive regulation of glycolytic process GO:0045821 9.56 IGF1 INS
19 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.56 GH1 GHR IGF1 INS
20 insulin-like growth factor receptor signaling pathway GO:0048009 9.55 GHR IGF1
21 growth hormone receptor signaling pathway GO:0060396 9.52 GH1 GHR
22 positive regulation of JAK-STAT cascade GO:0046427 9.5 GH1 GHR PRL
23 negative regulation of feeding behavior GO:2000252 9.49 INS TRH
24 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.33 GH1 GHR IGF1
25 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.13 GH1 GHR PRL
26 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 8.92 GH1 GHRH IGF1 IGFBP3

Molecular functions related to Hyperpituitarism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 IGF1 INS
2 hormone activity GO:0005179 9.17 GH1 IGF1 INS POMC PRL SST
3 insulin-like growth factor receptor binding GO:0005159 9.16 IGF1 INS
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperpituitarism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....